Quantitative determination of pegylated consensus interferon in rhesus monkey serum using a competitive enzyme-linked immunosorbent assay

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 4, 2009, Pages 543-549

  Cao, Jin ^a   Du, Yu ^a   Tian, Hong ^a   Gao, Xiang Dong ^a   Yao, Wen Bing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Competitive ELISA; Monoclonal antibody; PEG CIFN; Pharmacokinetics; Rhesus monkey

Indexed keywords

ANTIVIRUS AGENT; CONSENSUS INTERFERON; PEGYLATED CONSENSUS INTERFERON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL VEIN; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RHESUS MONKEY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; INTERFERON ALFA-2B; MACACA MULATTA; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; REPRODUCIBILITY OF RESULTS;

MACACA MULATTA;

EID: 70449087470     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970902814111     Document Type: Article

References (23)

1. Blatt L.M., Davis J.M., Klein S.B. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. Interferon Cytokine Res. 1996, 16(7), 489-499.
2. Ozes O.N., Reiter Z., Klein S. A comparison of interferon-con 1 with natural recombinant interferon-alpha: antiviral, antiproliferative, and natural killer-inducing activities. Interferon Res. 1992, 12(1), 55-59.
3. Pepinsky R.B., LePage D.J., Gill A. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferonb- 1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 2001, 297(3), 1059-1066.
4. Roberts M.J., Bentley M.D., Harris J.M. Chemistry for peptide and protein PEFylation. Adv. Drug. Deliv. Rev. 2002, 54(4), 459-476.
5. Harris J.M., Martin N.E., Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40(7), 539-551.
6. Delgado C., Francis G.M., Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug. Carrier. Syst. 1992, 9(3-4), 249-304.
7. He X.H., Shaw P.C., Tam S.C. Reducing the immunogenicity and improving the in vivo activity of tricosanthin by site-directed pegylation. Life Sci. 1999, 65(4), 355-368.
8. Antoni K., Harris J.M. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C. Control Release. 2001, 72(1-3), 217-224.
9. Moshe T., Ashok R., Karen R. Phase I evalution of a 40-kDa branched-chain long-acting pegylated IFN--6255.
10. Robert J., Ashok R., Michelle G. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma G. J. Clin. Oncol. 2001, 19(5), 1312-1319.
11. Yeong W.J., Yu S.Y., Sung H.L. Long-acting interferon-2-2), 87-93.
12. Janie C., Carol A.G., Carl N.Y. Pharmacokinetics of recombinant human interferon -572.
13. Ralph W.N., Lane W., Melissa W. Systemic absorption and activity of recombinant consensus interferons after intratracheal instillation and aerosol administration. Pharm. Res. 1995, 12(12), 1889-1895.
14. Donald E.M., Berend N., Constantinos E. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon--270.
15. Blaire L.O., Henrik S.O., Bernardetta N. Pharmacokinetic and pharmacodynamic studies of a human serum albumininterferon- -548.
16. Paul G., Regine R.P., Claude R. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000, 32(3), 647-653.
17. Marcelo S., Jorge P., Frank W. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J. Hepatology 2006, 45(2), 204-213.
18. Karol S., Howard M.S. Monoclonal Antibodies. London: Blackwell Scientific, 1996.
19. Hui W., Wei L., Xia X. Establishment and evaluation of indirect competitive enzyme-linked immunosorbent assay for detecting the concentration of trypsiongen activation peptides. Int. J. Lab. Med. 2006, 27(3), 206-208.
20. Rubinstein S., Familletti P.C., Pestka S. Convenient assay for interferons. J. Virol. 1981, 37(2), 755-758.
21. Qingshan H., Jien Z., Hongyu W. Detection of recombinant lysostaphin using antibody sandwich enzyme-linked immunoadsorbent assay (ELISA). Chin. J. Biotech. 2007, 23(1), 117-121.
22. Guangji W. Pharmacokinetics. Chemical Industry Press, Beijing, China, 2005.
23. Yu D., Hong T., Xiangdong G., Wenbing Y. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon--484.